[1]吕丽娜,杨灿华.地中海贫血的诊疗现状及分子生物学研究[J].医学信息,2022,35(11):33-36.[doi:10.3969/j.issn.1006-1959.2022.11.010]
 LYU Li-na,YANG Can-hua.Diagnosis and Treatment Status of Thalassemia and Molecular Biology Research[J].Medical Information,2022,35(11):33-36.[doi:10.3969/j.issn.1006-1959.2022.11.010]
点击复制

地中海贫血的诊疗现状及分子生物学研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年11期
页码:
33-36
栏目:
综述
出版日期:
2022-06-01

文章信息/Info

Title:
Diagnosis and Treatment Status of Thalassemia and Molecular Biology Research
文章编号:
1006-1959(2022)11-0033-04
作者:
吕丽娜杨灿华
(广西医科大学附属武鸣医院血液内科,广西 南宁 530199)
Author(s):
LYU Li-naYANG Can-hua
(Department of Hematology,Wuming Hospital Affiliated to Guangxi Medical University,Nanning 530199,Guangxi,China)
关键词:
地中海贫血血红蛋白珠蛋白基因铁螯合剂无效红细胞生成
Keywords:
ThalassemiaHemoglobinGlobin geneIron chelatorIneffective erythropoiesis
分类号:
R556
DOI:
10.3969/j.issn.1006-1959.2022.11.010
文献标志码:
A
摘要:
地中海贫血是临床常见的遗传性慢性溶血性疾病,以珠蛋白肽链生成障碍为主要特征,目前该病的分子基础及遗传方式已较为明确,其诊疗方式及病理机制研究均取得了较大进展。本文现对地中海贫血的诊疗现状及分子生物学研究进行阐述。
Abstract:
Thalassemia is a common clinical hereditary hemolytic anemia disease, which is characterized by the disorder of globin peptide chain formation. At present, the molecular basis and genetic mode of the disease have been relatively clear, and great progress has been made in the research on its diagnosis, treatment and pathological mechanism. In this paper, the diagnosis and treatment status of thalassemia and molecular biology research are reviewed.

参考文献/References:

[1]范凤珍,陈倩,朱银梅,等.输血依赖型β地中海贫血小儿铁代谢与心肾功能的关系分析[J].安徽医药,2021,25(7):1379-1382.[2]谢琪,黄玲,吴霖浦,等.地中海贫血患儿的生长发育状况及营养风险[J].广西医学,2020,42(23):3047-3049.[3]Risoluti R,Materazzi S,Sorrentino F,et al.Update on thalassemia diagnosis:New insights and methods[J].Talanta,2018,183:216-222.[4]Viprakasit V,Ekwattanakit S.Clinical Classification,Screening and Diagnosis for Thalassemia[J].Hematol Oncol Clin North Am,2018,32(2):193-211.[5]Strocchio L,Locatelli F.Hematopoietic Stem Cell Transplantation in Thalassemia[J].Hematol Oncol Clin North Am,2018,32(2):317-328.[6]王明泉,高晶晶,谢仁伟,等.长期输血重型β地中海贫血患儿不规则抗体产生及其与RH因子和贫血基因突变位点的相关性分析[J].中国实验血液学杂志,2017,25(6):1756-1760.[7]徐冬云,张霜,梁小娟.宝安地区β地中海贫血患者HbF和HbA2受KLF1基因突变的作用分析[J].中国优生与遗传杂志,2020,28(9):1055-1057,1093.[8]Thein SL.Molecular basis of β thalassemia and potential therapeutic targets[J].Blood Cells Mol Dis,2018,70:54-65.[9]Albers E,Sbroggiò M,Martin-Gonzalez J,et al.A simple DNA recombination screening method by RT-PCR as an alternative to Southern blot[J].Transgenic Res,2017,26(3):429-434.[10]邓宇运,李雁.缺口PCR与PCR-荧光探针在地中海贫血中的诊断价值分析[J].甘肃医药,2020,39(7):622-623.[11]王天菊,陈利萍,王小芳,等.HLA新等位基因HLA-B$$$*67:07测序分析及确认[J].临床输血与检验,2017,19(5):482-486.[12]肖奇志,王格,李恋湘,等.不同原理的PCR方法用于地中海贫血产前诊断的验证应用[J].实用医学杂志,2017,33(6):994-996.[13]焦保权,李薇,刘芳.多重连接探针扩增技术诊断Prader-Willi综合征3例[J].中华实用儿科临床杂志,2016,31(20):1580-1581.[14]周献青,张岳,林华,等.地中海贫血患者血浆环状RNA的筛查及结果分析[J].海南医学,2020,31(22):2906-2910.[15]He J,Song W,Yang J,et al.Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population:the Dai nationality,China[J].Genet Med,2017,19(9):1022-1031.[16]刘晓静,江莲.促红细胞生成素不同用药时机治疗早产儿贫血的效果研究[J].中国全科医学,2017,20(32):3991-3995.[17]Mettananda S,Fisher CA,Hay D,et al.Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia[J].Nat Commun,2017,8(1):424.[18]Asshoff M,Petzer V,Warr MR,et al.Momelotinib inhibits ACVR1/ALK2,decreases hepcidin production,and ameliorates anemia of chronic disease in rodents[J].Blood,2017,129(13):1823-1830.[19]Casu C,Presti VL,Oikonomidou PR,et al.Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of beta-thalassemia intermedia and major[J].Haematologica,2018,103(2):e46-e49.[20]Cappellini MD,Viprakasit V,Taher AT,et al.A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia[J].New England Journal of Medicine,2020,382(13):1219-1231.[21]Thanuthanakhun N,Nuntakarn L,Sampattavanich S,et al.Investigation of FoxO3 dynamics during erythroblast development in β-thalassemia major[J].PloS One,2017,12(11):e187610.[22]Camaschella C,Pagani A,Nai A,et al.The Mutual Control of Iron and Erythropoiesis[J].International Journal of Laboratory Hematology,2016,38 Suppl 1:20-26.[23]Belmont A,Kwiatkowski JL.Deferiprone for the treatment of transfusional iron overload in thalassemia[J].Expert Rev Hematol,2017,10(6):493-503.[24]贺潇,李秋红,易四维,等.铁缺乏对地中海贫血筛查指标的影响[J].中国实验血液学杂志,2020,28(4):1312-1315.[25]郭丽,邱卫强.NTDT患者铁过载对肝脏功能、炎症及氧化应激反应的影响[J].热带医学杂志,2020,20(4):508-511,573.[26]Casu C,Oikonomidou PR,Chen H,et al.MinihepcidinPeptidesas Disease Modifiers Inmice Affected byβ-Thalassemia and Polycythemia Vera[J].Blood,2016,128(2):265-276.[27]Aghajan M,Casu C,Io Presti V,et al.Developing a Galnac-Conjugated TMPRSS6 Antisense Therapyfor the Treatmentofβ-Thalassemia[J].Blood,2016,128(25):1013.[28]Anderson ER,Taylor M,Xue X,et al.Intestinal HIF2αPromotes Tissue-Iron Accumulation in Disorders of Iron Overload with Anemia[J].Proc of Natl Acad Sci U S A,2013,110(50):e4922-e4930.[29]Mathews V,Balasubramanian P,Abraham A,et al.Allogeneic stem cell transplantation for thalassemia major in India[J].Pediatric Hematology Oncology Journal,2018,2(4):114-120.[30]Liang P,Ding C,Sun H,et al.Correction of β-thalassemia mutant by base editor in human embryos[J].Protein Cell,2017,8(11):811-822.[31]Kwiatkowski JL,Thompson AA,Rasko J,et al.Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study[J].Blood,2017,130(S1):360-360.

相似文献/References:

[1]丁慧强,杨 辉.AECOPD伴呼吸衰竭患者短期内撤机拔管的影响因素分析[J].医学信息,2019,32(01):106.[doi:10.3969/j.issn.1006-1959.2019.01.032]
 DING Hui-qiang,YANG Hui.Analysis of Influencing Factors of Ablation of AECOPD Patients with Respiratory Failure in Short-term[J].Medical Information,2019,32(11):106.[doi:10.3969/j.issn.1006-1959.2019.01.032]
[2]冉瑞图,苏 帅,唐先圣,等.影响PCNL术后出血栓塞治疗的主要因素分析[J].医学信息,2019,32(11):124.[doi:10.3969/j.issn.1006-1959.2019.11.036]
 RAN Rui-tu,SU Shuai,TANG Xian-sheng,et al.Analysis of Main Factors Affecting Thromboembolism After PCNL[J].Medical Information,2019,32(11):124.[doi:10.3969/j.issn.1006-1959.2019.11.036]
[3]黄正辉,陈小兵,刘高伦.血液透析患者贫血与超敏CRP的相关性研究[J].医学信息,2019,32(19):112.[doi:10.3969/j.issn.1006-1959.2019.19.035]
 HUANG Zheng-hui,CHEN Xiao-bing,LIU Gao-lun.Correlation Study Between Anemia and Hypersensitive C-reactive Protein in Hemodialysis Patients[J].Medical Information,2019,32(11):112.[doi:10.3969/j.issn.1006-1959.2019.19.035]
[4]邓小春,蒋运兰,肖 力,等.使用线性蠕动机制输液泵输血安全性的Meta分析[J].医学信息,2020,33(07):82.[doi:10.3969/j.issn.1006-1959.2020.07.023]
 DENG Xiao-chun,JIANG Yun-lan,XIAO Li,et al.Meta-analysis of the Safety of Transfusion Pump Using Linear Peristaltic Mechanism[J].Medical Information,2020,33(11):82.[doi:10.3969/j.issn.1006-1959.2020.07.023]
[5]刘 洋,吴佳南.MCV与MCH联合检测鉴别诊断地中海贫血与缺铁性贫血的价值[J].医学信息,2020,33(13):169.[doi:10.3969/j.issn.1006-1959.2020.13.053]
 LIU Yang,WU Jia-nan.The Value of Combined Detection of MCV and MCH in the Differential Diagnosis of Thalassemia and Iron Deficiency Anemia[J].Medical Information,2020,33(11):169.[doi:10.3969/j.issn.1006-1959.2020.13.053]
[6]吴智明,曹晓强,林 翀,等.海南省文昌、定安、东方、乐东四市县居民对地中海贫血相关知识知晓度的分析[J].医学信息,2021,34(11):133.[doi:10.3969/j.issn.1006-1959.2021.11.037]
 WU Zhi-ming,CAO Xiao-qiang,LIN Chong,et al.Analysis of the Awareness of Thalassemia-related Knowledge Among Residents in Wenchang,Ding’an,Dongfang,and Ledong Cities and Counties in Hainan Province[J].Medical Information,2021,34(11):133.[doi:10.3969/j.issn.1006-1959.2021.11.037]
[7]吴文钦,熊戌霞,蔡梦珊.深圳市龙华区地中海贫血基因分型情况分析[J].医学信息,2021,34(14):142.[doi:10.3969/j.issn.1006-1959.2021.14.039]
 WU Wen-qin,XIONG Xu-xia,CAI Meng-shan.Analysis on the Genotyping of Thalassemia in Longhua District,Shenzhen[J].Medical Information,2021,34(11):142.[doi:10.3969/j.issn.1006-1959.2021.14.039]
[8]欧阳莉,赖章辉,李 峰.血液检验诊断和鉴别缺铁性贫血及地中海贫血的意义研究[J].医学信息,2023,36(09):139.[doi:10.3969/j.issn.1006-1959.2023.09.029]
 OUYANG Li,LAI Zhang-hui,LI Feng.The Significance of Blood Test in the Differential Diagnosis of Iron Deficiency Anemia and Thalassemia[J].Medical Information,2023,36(11):139.[doi:10.3969/j.issn.1006-1959.2023.09.029]
[9]王金英.卡前列甲酯栓联合麦角新碱预防瘢痕子宫剖宫产产后出血的临床效果及安全性[J].医学信息,2023,36(23):107.[doi:10.3969/j.issn.1006-1959.2023.23.027]
 WANG Jin-ying.Clinical Effect and Safety of Methyl Carprost Suppositories Combined with Ergonovine in Preventing Postpartum Hemorrhage of Cesarean Section of Scar Uterus[J].Medical Information,2023,36(11):107.[doi:10.3969/j.issn.1006-1959.2023.23.027]

更新日期/Last Update: 1900-01-01